Top-Rated StocksTop-RatedNASDAQ:QNCX Quince Therapeutics (QNCX) Stock Price, News & Analysis $1.78 -0.17 (-8.72%) Closing price 04:00 PM EasternExtended Trading$1.79 +0.01 (+0.56%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Quince Therapeutics Stock (NASDAQ:QNCX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Quince Therapeutics alerts:Sign Up Key Stats Today's Range$1.62▼$2.0550-Day Range$1.54▼$1.9552-Week Range$0.69▼$2.45Volume1.62 million shsAverage Volume242,062 shsMarket Capitalization$95.60 millionP/E RatioN/ADividend YieldN/APrice Target$8.14Consensus RatingBuy Company Overview Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California. Read More Quince Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreQNCX MarketRank™: Quince Therapeutics scored higher than 67% of companies evaluated by MarketBeat, and ranked 331st out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingQuince Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialQuince Therapeutics has a consensus price target of $8.14, representing about 357.5% upside from its current price of $1.78.Amount of Analyst CoverageQuince Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Quince Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Quince Therapeutics are expected to grow in the coming year, from ($1.21) to ($0.79) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quince Therapeutics is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quince Therapeutics is -1.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuince Therapeutics has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Quince Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.12% of the float of Quince Therapeutics has been sold short.Short Interest Ratio / Days to CoverQuince Therapeutics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Quince Therapeutics has recently decreased by 2.47%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldQuince Therapeutics does not currently pay a dividend.Dividend GrowthQuince Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.12% of the float of Quince Therapeutics has been sold short.Short Interest Ratio / Days to CoverQuince Therapeutics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Quince Therapeutics has recently decreased by 2.47%, indicating that investor sentiment is improving. News and Social Media3.2 / 5News Sentiment0.81 News SentimentQuince Therapeutics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Quince Therapeutics this week, compared to 2 articles on an average week.Search Interest13 people have searched for QNCX on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days.MarketBeat FollowsOnly 10 people have added Quince Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -9% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Quince Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders16.80% of the stock of Quince Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.75% of the stock of Quince Therapeutics is held by institutions.Read more about Quince Therapeutics' insider trading history. Receive QNCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quince Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QNCX Stock News HeadlinesQuince Therapeutics, Inc. (QNCX) Analyst/Investor Day TranscriptOctober 2, 2025 | seekingalpha.comQuince Therapeutics (NASDAQ:QNCX) Trading Up 1.2% - What's Next?October 1, 2025 | americanbankingnews.comArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.October 7 at 2:00 AM | Banyan Hill Publishing (Ad)Quince Therapeutics (NASDAQ:QNCX) Earns "Buy" Rating from D. Boral CapitalSeptember 27, 2025 | americanbankingnews.comQuince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling StudySeptember 25, 2025 | businesswire.comQuince Therapeutics, Inc. - Special CallSeptember 24, 2025 | seekingalpha.comQuince Therapeutics to Host Virtual Investor Day on October 2, 2025September 11, 2025 | businesswire.comQuince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | businesswire.comSee More Headlines QNCX Stock Analysis - Frequently Asked Questions How have QNCX shares performed this year? Quince Therapeutics' stock was trading at $1.87 on January 1st, 2025. Since then, QNCX stock has decreased by 4.8% and is now trading at $1.78. How were Quince Therapeutics' earnings last quarter? Quince Therapeutics, Inc. (NASDAQ:QNCX) issued its quarterly earnings data on Monday, August, 11th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.06. How do I buy shares of Quince Therapeutics? Shares of QNCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Quince Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Quince Therapeutics investors own include Athenex (ATNX), PayPal (PYPL), SoFi Technologies (SOFI), TherapeuticsMD (TXMD), Achilles Therapeutics (ACHL), Agile Therapeutics (AGRX) and Aytu BioPharma (AYTU). Company Calendar Last Earnings8/11/2025Today10/07/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:QNCX CIK1662774 Webwww.quincetx.com Phone(650) 910-5717FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Price Target for Quince Therapeutics$8.14 High Price Target$11.00 Low Price Target$4.00 Potential Upside/Downside+357.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$56.83 million Net MarginsN/A Pretax MarginN/A Return on Equity-187.49% Return on Assets-42.47% Debt Debt-to-Equity Ratio1.45 Current Ratio5.00 Quick Ratio5.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book2.58Miscellaneous Outstanding Shares53,710,000Free Float44,690,000Market Cap$95.60 million OptionableOptionable Beta1.07 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:QNCX) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quince Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quince Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.